Drug delivery in glioblastoma therapy: a review on nanoparticles targeting MGMT-mediated resistance.
Inês David TorresJoana Angélica LoureiroManuel A N CoelhoMaria do Carmo PereiraMaria João RamalhoPublished in: Expert opinion on drug delivery (2022)
To overcome therapeutic limitations, nano-based approaches have been proposed as a suitable solution to improve drug accumulation in the brain tumor tissue and decrease systemic toxicity. DDS to overcome MGMT-mediated resistance in GBM have been mostly developed to deliver MGMT inhibitors and for gene therapy to modulate MGMT gene expression.